Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Baxter
US Army
McKinsey
Chinese Patent Office
Boehringer Ingelheim

Generated: August 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,251,666

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,251,666
Title: Nucleic acid catalysts comprising L-nucleotide analogs
Abstract:A nucleic acid catalyst comprising at least one L-nucleotide substitution.
Inventor(s): Beigelman; Leonid (Longmont, CO)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:09/048,825
Patent Claims:1. A ribozyme comprising at least one L-nucleotide substitution.

2. The ribozyme of claim 1, wherein said L-nucleotide has the formula I: ##STR2##

wherein, X is a nucleic acid base, which may be modified or unmodified, or H; Y is a phosphorus-containing group; R.sub.1 is H, OH or other 2'-modifications; and R.sub.2 is a blocking group or a phosphorus-containing group.

3. The ribozymne of claim 1, wherein said ribozyme has an endonuclease activity.

4. The ribozyme of claim 1, wherein said ribozyme is capable of cleaving a peptide linkage.

5. The ribozyme of claim 2, wherein said ribozyme cleaves a separate nucleic acid molecule.

6. The ribozyme of claim 1, wherein said ribozyme ligates separate nucleic acid molecules.

7. The ribozyme of claim 5, wherein said separate nucleic acid molecule is a ribonucleic acid molecule.

8. The ribozyme of claim 1, wherein said ribozyme consists of L-nucleotides at every position in the ribozyme.

9. The ribozyme of claim 3, wherein said ribozyme is in a hammerhead ribozyme motif.

10. The ribozyme of claim 3, wherein said ribozyme is in a hairpin ribozyme motif.

11. The ribozyme of claim 3, wherein said ribozyme is in a hepatitis delta virus, group I intron, group II intron, VS RNA or RNase P RNA motif.

12. The ribozyme of claim 1, wherein said ribozyme comprises at least two said L-nucleotide substitutions which may be same or different.

13. The ribozyme of claim 1, wherein said ribozyme comprises at least one D-nucleotide residue.

14. The ribozyme of claim 5, wherein said ribozyme comprises between 12 and 100 bases complementary to said separate nucleic acid molecule.

15. The ribozyme of claim 5, wherein said ribozyme comprises between 14 and 24 bases complementary to said separate nucleic acid molecule.

16. The ribozyme of claim 2, wherein said R.sub.1 is OH.

17. The ribozyme of claim 2, wherein said R.sub.1 is amino.

18. The ribozyme of claim 2, wherein said R.sub.1 is alkoxy.

19. The ribozyme of claim 2, wherein said X is selected from the group consisting of adenine, guanine, uracil, and cytosine.

20. A mammalian cell comprising the ribozyme of claim 1.

21. The mammalian cell of claim 20, wherein said mammalian cell is a human cell.

22. A pharmaceutical composition comprising the ribozyme of claim 1.

23. A method for modulating expression of a gene in a mammalian cell by administering to said cell at least one ribozyme of claim 1.

24. A method of cleaving a separate nucleic acid molecule comprising, contacting the ribozyme of claim 1 with said separate nucleic acid molecule under conditions suitable for the cleavage.

25. The method of claim 24, wherein said cleavage is carried out in the presence of a divalent cation.

26. The method of claim 25, wherein said divalent cation is Mg.sup.2+.

27. The ribozyme of claim 1, wherein said ribozyme is chemically synthesized.

28. The ribozyme of claim 9, wherein said L-nucleotide substitution is at positions 4, or 7 of said hammerhead ribozyme motif.

29. The ribozyme of claim 9, wherein said L-nucleotide substitution is at positions 4 and 7 of said hammerhead ribozyme motif.

30. The ribozyme of claim 9, wherein said L-nucleotide substitution is at the 3' terminal position of said hammerhead ribozyme motif.

Details for Patent 6,251,666

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-03-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-03-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-03-31 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,251,666

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 9828317 Jul 02, 1998
World Intellectual Property Organization (WIPO) 9828317 Sep 03, 1998
United States of America 2002052037 May 02, 2002
United States of America 6159951 Dec 12, 2000
United States of America 6248878 Jun 19, 2001
United States of America 6506888 Jan 14, 2003
United States of America 6602858 Aug 05, 2003
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
US Department of Justice
McKesson
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.